{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:17:32Z","timestamp":1745554652312,"version":"3.40.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"DOI":"10.7759\/cureus.82881","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T08:03:03Z","timestamp":1745481783000},"source":"Crossref","is-referenced-by-count":0,"title":["Fournier's Gangrene During Lenvatinib Treatment for Hepatocarcinoma"],"prefix":"10.7759","author":[{"given":"Simone","family":"Rota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"de Scordilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Vida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Guardascione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Zdjelar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bottos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Cabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Maffeis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ongaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Foltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo M","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al.. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018, 391:1163-73. 10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto Y","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, et al.. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014, 6:18. 10.1186\/2045-824X-6-18","journal-title":"Vasc Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda K","year":"2017","unstructured":"Ikeda K, Kudo M, Kawazoe S, et al.. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017, 52:512-9. 10.1007\/s00535-016-1263-4","journal-title":"J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis","volume":"7","author":"Rimini M","year":"2022","unstructured":"Rimini M, Rimassa L, Ueshima K, et al.. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022, 7:100591. 10.1016\/j.esmoop.2022.100591","journal-title":"ESMO Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng Z","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, et al.. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023, 41:117-27. 10.1200\/JCO.22.00392","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA432","article-title":"EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization","volume":"42","author":"Lencioni R","year":"2024","unstructured":"Lencioni R, Kudo M, Erinjeri J, et al.. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol. 2024, 42:LBA432. 10.1200\/JCO.2024.42.3_suppl.LBA432","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2277","article-title":"Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): phase III LEAP-012 study","volume":"35","author":"Llovet J","year":"2024","unstructured":"Llovet J, Finn R S, Ren Z, et al.. Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): phase III LEAP-012 study. Ann Oncol. 2024, 35:S1229.","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2016.3.157","article-title":"Fournier's gangrene. A clinical review","volume":"88","author":"Singh A","year":"2016","unstructured":"Singh A, Ahmed K, Aydin A, Khan MS, Dasgupta P. Fournier's gangrene. A clinical review. Arch Ital Urol Androl. 2016, 88:157-64. 10.4081\/aiua.2016.3.157","journal-title":"Arch Ital Urol Androl"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.12.030","article-title":"Fournier's gangrene mortality: a 17-year systematic review and meta-analysis","volume":"92","author":"El-Qushayri AE","year":"2020","unstructured":"El-Qushayri AE, Khalaf KM, Dahy A, et al.. Fournier's gangrene mortality: a 17-year systematic review and meta-analysis. Int J Infect Dis. 2020, 92:218-25. 10.1016\/j.ijid.2019.12.030","journal-title":"Int J Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6109(16)46485-6","article-title":"Fournier's gangrene","volume":"74","author":"Laucks SS 2nd","year":"1994","unstructured":"Laucks SS 2nd. Fournier's gangrene. Surg Clin North Am. 1994, 74:1339-52. 10.1016\/s0039-6109(16)46485-6","journal-title":"Surg Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14998","article-title":"Mortality associated with Fournier's gangrene remains unchanged over 25\u00a0years","volume":"125","author":"Radcliffe RS","year":"2020","unstructured":"Radcliffe RS, Khan MA. Mortality associated with Fournier's gangrene remains unchanged over 25\u00a0years. BJU Int. 2020, 125:610-6. 10.1111\/bju.14998","journal-title":"BJU Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1600673","article-title":"Necrotizing soft-tissue infections","volume":"377","author":"Stevens DL","year":"2017","unstructured":"Stevens DL, Bryant AE. Necrotizing soft-tissue infections. N Engl J Med. 2017, 377:2253-65. 10.1056\/NEJMra1600673","journal-title":"N Engl J Med"},{"key":"ref13","article-title":"A case of Fournier's gangrene during second-line IRIS plus bevacizumab chemotherapy for rectal and anal canal cancer [Article in Japanese]","volume":"49","author":"Imamura S","year":"2022","unstructured":"Imamura S, Ogura N, Aoki Y, et al.. A case of Fournier's gangrene during second-line IRIS plus bevacizumab chemotherapy for rectal and anal canal cancer [Article in Japanese]. Gan To Kagaku Ryoho. 2022, 49:597-9.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref14","article-title":"A case of Fournier's gangrene caused by small intestinal perforation during bevacizumab combination chemotherapy [Article in Japanese]","volume":"43","author":"Ishida T","year":"2016","unstructured":"Ishida T, Shinozaki H, Ozawa H, et al.. A case of Fournier's gangrene caused by small intestinal perforation during bevacizumab combination chemotherapy [Article in Japanese]. Gan To Kagaku Ryoho. 2016, 43:909-11.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref15","article-title":"Two cases of Fournier's gangrene that occurred during chemotherapy for rectal cancer [Article in Japanese]","volume":"44","author":"Koyama M","year":"2017","unstructured":"Koyama M, Kitazawa M, Ehara T, Yamamoto Y, Suzuki A, Miyagawa Y, Miyagawa S. Two cases of Fournier's gangrene that occurred during chemotherapy for rectal cancer [Article in Japanese]. Gan To Kagaku Ryoho. 2017, 44:169-71.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1308\/rcsann.2017.0143","article-title":"Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report","volume":"99","author":"Gonzaga-L\u00f3pez A","year":"2017","unstructured":"Gonzaga-L\u00f3pez A, Mu\u00f1oz-Rodriguez J, Ruiz-Casado A. Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report. Ann R Coll Surg Engl. 2017, 99:e225-6. 10.1308\/rcsann.2017.0143","journal-title":"Ann R Coll Surg Engl"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2010.n.008","article-title":"Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer","volume":"9","author":"Gamboa EO","year":"2010","unstructured":"Gamboa EO, Rehmus EH, Haller N. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer. Clin Colorectal Cancer. 2010, 9:55-8. 10.3816\/CCC.2010.n.008","journal-title":"Clin Colorectal Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620946556","article-title":"Fulminant Fournier's gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel","volume":"11","author":"Rakusic Z","year":"2020","unstructured":"Rakusic Z, Krpan AM, Sjekavica I. Fulminant Fournier's gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel. Ther Adv Drug Saf. 2020, 11:2042098620946556. 10.1177\/2042098620946556","journal-title":"Ther Adv Drug Saf"},{"key":"ref19","article-title":"A case of Fournier's gangrene due to perforation of lower rectal cancer during chemotherapy [Article in Japanese]","volume":"44","author":"Fukuhisa H","year":"2017","unstructured":"Fukuhisa H, Baba K, Kita Y, Tanabe H, Ijichi T, Mori S, Natsugoe S. A case of Fournier's gangrene due to perforation of lower rectal cancer during chemotherapy [Article in Japanese]. Gan To Kagaku Ryoho. 2017, 44:935-7.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.125195","article-title":"Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma","volume":"46","author":"Sendur MA","year":"2014","unstructured":"Sendur MA, Aksoy S, \u00d6zdemir NY, Zengin N. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma. Indian J Pharmacol. 2014, 46:125-6. 10.4103\/0253-7613.125195","journal-title":"Indian J Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-198","article-title":"Necrotizing fasciitis caused by Haemophilus influenzae type b in a patient with rectal cancer treated with combined bevacizumab and chemotherapy: a case report","volume":"14","author":"Ugai T","year":"2014","unstructured":"Ugai T, Norizuki M, Mikawa T, Ohji G, Yaegashi M. Necrotizing fasciitis caused by Haemophilus influenzae type b in a patient with rectal cancer treated with combined bevacizumab and chemotherapy: a case report. BMC Infect Dis. 2014, 14:198. 10.1186\/1471-2334-14-198","journal-title":"BMC Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2165\/11597600-000000000-00000","article-title":"Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis","volume":"35","author":"Shamloo BK","year":"2012","unstructured":"Shamloo BK, Chhabra P, Freedman AN, Potosky A, Malin J, Weiss Smith S. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf. 2012, 35:507-18. 10.2165\/11597600-000000000-00000","journal-title":"Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2020.2031","article-title":"Fournier's gangrene during lenvatinib treatment: a case report","volume":"12","author":"Barone M","year":"2020","unstructured":"Barone M, Grani G, Ramundo V, Garritano T, Durante C, Falcone R. Fournier's gangrene during lenvatinib treatment: a case report. Mol Clin Oncol. 2020, 12:588-91. 10.3892\/mco.2020.2031","journal-title":"Mol Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3907-24","article-title":"Fournier's gangrene in the course of treatment of advanced hepatocellular carcinoma with molecular-targeted therapy","volume":"64","author":"Komeda Y","year":"2025","unstructured":"Komeda Y, Nagamatsu S, Kaya D, et al.. Fournier's gangrene in the course of treatment of advanced hepatocellular carcinoma with molecular-targeted therapy. Intern Med. 2025, 64:673-8. 10.2169\/internalmedicine.3907-24","journal-title":"Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2014.00036","article-title":"Current concepts in the management of necrotizing fasciitis","volume":"1","author":"Misiakos EP","year":"2014","unstructured":"Misiakos EP, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, Machairas A. Current concepts in the management of necrotizing fasciitis. Front Surg. 2014, 1:36. 10.3389\/fsurg.2014.00036","journal-title":"Front Surg"},{"key":"ref26","article-title":"Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia","volume":"170","author":"Clayton MD","year":"1990","unstructured":"Clayton MD, Fowler JE Jr, Sharifi R, Pearl RK. Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet. 1990, 170:49-55.","journal-title":"Surg Gynecol Obstet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12758","article-title":"Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis","volume":"81","author":"Zhang X","year":"2016","unstructured":"Zhang X, Ran Y, Shao Y, Wang K, Zhu Y. Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016, 81:33-40. 10.1111\/bcp.12758","journal-title":"Br J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-010-9197-6","article-title":"Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review","volume":"14","author":"Walraven M","year":"2011","unstructured":"Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis. 2011, 14:135-41. 10.1007\/s10456-010-9197-6","journal-title":"Angiogenesis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-015-9752-x","article-title":"Bowel perforation after treatment with sorafenib: a case report and review of literature","volume":"47","author":"Hamdeh S","year":"2016","unstructured":"Hamdeh S, Upadhyay S, Khanal N, Lanspa S. Bowel perforation after treatment with sorafenib: a case report and review of literature. J Gastrointest Cancer. 2016, 47:420-2. 10.1007\/s12029-015-9752-x","journal-title":"J Gastrointest Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2018.17316","article-title":"Intestinal perforation after regorafenib usage","volume":"29","author":"Sar\u0131c\u0131 B","year":"2018","unstructured":"Sar\u0131c\u0131 B, Karaka\u015f S, Uylas U, Akta\u015f A, Dikilita\u015f M, Kayaalp C. Intestinal perforation after regorafenib usage. Turk J Gastroenterol. 2018, 29:245-7. 10.5152\/tjg.2018.17316","journal-title":"Turk J Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815Y.0000000053","article-title":"Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials","volume":"28","author":"Wang Z","year":"2016","unstructured":"Wang Z, Zhang J, Zhang L, Liu P, Xie Y, Zhou Q. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. J Chemother. 2016, 28:328-34. 10.1179\/1973947815Y.0000000053","journal-title":"J Chemother"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13802","article-title":"Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo","volume":"39","author":"Ogasawara S","year":"2019","unstructured":"Ogasawara S, Mihara Y, Kondo R, Kusano H, Akiba J, Yano H. Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo. Anticancer Res. 2019, 39:5973-82. 10.21873\/anticanres.13802","journal-title":"Anticancer Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1159\/000510911","article-title":"Lenvatinib-induced tumor-related hemorrhages in patients with large hepatocellular carcinomas","volume":"99","author":"Uchida-Kobayashi S","year":"2021","unstructured":"Uchida-Kobayashi S, Kageyama K, Yamamoto A, et al.. Lenvatinib-induced tumor-related hemorrhages in patients with large hepatocellular carcinomas. Oncology. 2021, 99:186-91. 10.1159\/000510911","journal-title":"Oncology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/his.15013","article-title":"Histological findings of thyroid cancer after lenvatinib therapy","volume":"83","author":"Okubo Y","year":"2023","unstructured":"Okubo Y, Toda S, Sato S, et al.. Histological findings of thyroid cancer after lenvatinib therapy. Histopathology. 2023, 83:657-63. 10.1111\/his.15013","journal-title":"Histopathology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1159\/000525569","article-title":"Bowel perforation in a patient with hepatocellular carcinoma during lenvatinib treatment","volume":"16","author":"Mizokami K","year":"2022","unstructured":"Mizokami K, Watanabe A, Yamaguchi E, Saito A. Bowel perforation in a patient with hepatocellular carcinoma during lenvatinib treatment. Case Rep Gastroenterol. 2022, 16:502-6. 10.1159\/000525569","journal-title":"Case Rep Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/329850-fourniers-gangrene-during-lenvatinib-treatment-for-hepatocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T08:03:04Z","timestamp":1745481784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/329850-fourniers-gangrene-during-lenvatinib-treatment-for-hepatocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.82881","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}